Male Breast Carcinoma
Stereotactic radiosurgery for brain metastases from male breast cancer: a multicenter retrospective study.
Duzkalir AH, et al
A multicenter retrospective study of 19 male breast cancer patients with 185 brain metastases treated with stereotactic radiosurgery (SRS) achieved an exceptionally high crude local control rate of 97.3% and a median overall survival of 28.0 months. Patients with controlled systemic disease at the t…
Source →"The marginalized": A qualitative review of the illness experiences and psychological experiences of male breast cancer patients.
Kong L, et al
A qualitative synthesis of 16 studies on male breast cancer (MBC) patients identified four core themes: significant stress following diagnosis, emotional changes throughout the disease course, diverse coping strategies, and active self-reconstruction after illness. The review, drawing on databases i…
Source →The burden of male breast cancer (MBC) in the GBD Central, Eastern, and Western Europe Regions from 1990 to 2023: Results from the Global Burden of Disease Study 2023.
Passera R, et al
The burden of male breast cancer (MBC) is rising across Europe, with the most striking increase observed in Central Europe, where the age-standardized incidence rate (ASIR) nearly doubled from 0.54 (0.40–0.76) to 1.05 (0.70–1.52) per 100,000 between 1990 and 2023. Using data from the Global Burden o…
Source →Decoding age-stratified clinical and molecular heterogeneity in male breast cancer through multiomic profiling.
Gao Z, et al
A multiomic study of 347 male breast cancer patients at Fudan University Shanghai Cancer Center found that younger patients (≤55 years) had significantly worse 5-year recurrence-free survival compared to older patients (hazard ratio=2.19, P=0.018), along with higher rates of HER2-positive (14.91% vs…
Source →The Association of 5-α Reductase Inhibitors for Benign Prostatic Hyperplasia With Development of Male Breast Disease and Erectile Dysfunction: A Retrospective Cohort Study of TriNetX Database.
Titus RS, et al
A large retrospective cohort study of 550,622 propensity score-matched patients found no statistically significant association between 5-α reductase inhibitor (5ARI) use and male breast cancer (MBC), with a relative risk of 1.09 (95% CI: 0.94–1.27), including when finasteride (RR 1.12; 95% CI: 0.96–…
Source →Breast reconstruction and symmetry restoration using a TDAP flap in a male patient following breast cancer treatment.
Chakari W, et al
A case report in BMJ Case Reports demonstrates that the thoracodorsal artery perforator (TDAP) flap is a viable, low-morbidity reconstructive option for male breast cancer patients seeking chest symmetry restoration following mastectomy. In a single male patient treated for breast cancer, the TDAP f…
Source →Effective Control of Synchronous Male Breast and Prostate Cancer with Androgen Deprivation Therapy: A Case Report.
Furukawa M, et al
A 74-year-old Japanese man diagnosed with synchronous estrogen receptor (ER)-positive, androgen receptor (AR)-positive male breast cancer (cStage IIA) and metastatic prostate cancer (Stage IV) achieved marked tumor regression in the breast lesion following androgen deprivation therapy (ADT), with su…
Source →Cardiorespiratory fitness and male breast cancer association: The ETHOS cohort.
Faselis C, et al
A landmark study of 777,618 U.S. male Veterans found that higher cardiorespiratory fitness (CRF) is independently associated with a substantially lower risk of male breast cancer: men in the highest fitness quartile had a 41% lower risk compared to the least fit group (HR = 0.59; 95% CI: 0.44–0.81).…
Source →Molecular and immune profiling of HER2-low, HER2 ultra-low, and HER2-null male breast cancer.
Trapani D, et al
A molecular study of 214 male breast tumors found that HER2-null tumors (30.8% of cases) represent the most biologically distinct subgroup within the HER2-negative spectrum, characterized by enriched neutrophil infiltration and upregulation of stemness-associated genes (NANOG, KLF4, POU5F1) and CEAC…
Source →Mapping the invisible: a Bayesian spatio-temporal analysis of male breast cancer mortality inequalities across Spanish provinces, 1999-2023.
Cayuela L, et al
A first-of-its-kind nationwide Bayesian spatio-temporal analysis of 1,931 male breast cancer deaths across Spain's 52 provinces from 1999 to 2023 found a significant national decline in mortality, with relative risk falling from 1.16 (posterior probability 0.96) in 1999 to 0.89 (posterior probabilit…
Source →A Mystery in the Male Breast: Immunomorphological Confirmation of Invasive Papillary Carcinoma in an Elderly.
Adamu ZA, et al
Clinicians in Nigeria have confirmed a rare case of male invasive papillary carcinoma (IPC) of the breast in an 85-year-old patient, with histopathology revealing over 90% papillary architecture, absence of a myoepithelial layer, and Nottingham Grade 2 morphology. Immunohistochemistry demonstrated d…
Source →Male breast cancer: from extrapolated practice to evidence-based care.
Liu B, et al
A new narrative review in The Oncologist concludes that male breast cancer, which accounts for approximately 1% of all breast cancer cases, remains critically understudied and its clinical management continues to rely on evidence extrapolated from female patient cohorts rather than male-specific pro…
Source →Uncovering an uncommon diagnosis: Encapsulated papillary carcinoma of the male breast in a Jordanian patient-A case report.
Alahmed A, et al
A 58-year-old Jordanian male was diagnosed with Encapsulated Papillary Carcinoma (EPC) of the breast, an uncommon low-grade malignancy representing only 2%-3% of male breast cancers, after a mass he had noticed six years earlier was initially misidentified as a lipoma. Preoperative imaging revealed …
Source →Male breast carcinoma in a 45-year-old without known risk factors: case report and literature review.
Subedi S, et al
A 45-year-old man with no known risk factors was diagnosed with invasive ductal carcinoma of the left breast accompanied by axillary lymphadenopathy, highlighting that male breast cancer — which accounts for approximately 1% of all breast neoplasms and typically occurs after age 60 — can present in …
Source →Montgomery Tubercles in the Male Areola: Histological Observations and a Brief About Past Investigators.
Pai SA, et al
A histological study confirms that Montgomery tubercles — glandular structures long debated in the literature — are indeed present in the male areola, with definite tubercles identified in 2 of 11 male breast carcinoma cases and putative tubercles in 2 additional cases. Serial hematoxylin-and-eosin-…
Source →